Frank E. Thomas - 29 May 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Reporting relationship: Director
Issuer ticker: SPRO
Reported as of: 29 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 May 2024, 16:15:59 UTC
Prior SEC filing: 15 Feb 2024
Next SEC filing: 14 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Satyavrat Shukla, Attorney-in-Fact for Frank E. Thomas

Key filing fact

Frank E. Thomas filed Form 4 for Spero Therapeutics, Inc. (SPRO) on 30 May 2024.

Key facts

This page summarizes Frank E. Thomas's Form 4 filing for Spero Therapeutics, Inc. (SPRO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 May 2024, 16:15.

Change

Previous filing in this sequence was filed on 15 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRO transaction

Common Stock

Award

Transaction value: $0
Shares: +20,000
Change %: +57%
Price: $0.000000
Shares after: 55,000
Date: 29 May 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date.